OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)

Background: In a Phase II study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD (Fleseriu M et al. Pituitary 2016;19:138-48). We report the efficacy and safety of osilodrostat in a large CD patient population in the first...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Endocr Soc
Glavni autori: Biller, Beverly MK, Newell-Price, John, Fleseriu, Maria, Bertagna, Xavier, Findling, James, Shimatsu, Akira, Lee, Eun Jig, Gu, Feng, Auchus, Richard, Leelawattana, Rattana, Lacroix, André, Kim, Jung Hee, Laplanche, Audrey, O'Connell, Paul, Tauchmanova, Libuse, Pedroncelli, Alberto, Pivonello, Rosario
Format: Artigo
Jezik:Inglês
Izdano: Endocrine Society 2019
Teme:
Neuroendocrinology and Pituitary
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6555000/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR16-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items